What is it prescribed for? ZAYNICH is a medication used to treat adults with advanced cancer that has progressed after prior treatments. It is typically used in patients whose cancer has specific features identified through testing and who have limited remaining treatment options. Advanced cancers can become resistant to standard therapies over time, making them...
What is it prescribed for? BAXFENDY is prescribed for adults with high blood pressure (hypertension). High blood pressure is a common condition that increases the risk of heart attack, stroke, heart failure, and kidney disease if left untreated. Many patients need more than one medication to control their blood pressure properly. BAXFENDY combines two medicines into...
LIFYORLI is prescribed in combination with nab-paclitaxel chemotherapy for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have already received one to three prior systemic treatment regimens, including at least one that contained bevacizumab
Hepcludex is prescribed for adults with chronic hepatitis delta virus (HDV) infection who do not have cirrhosis or who have compensated cirrhosis. Hepatitis D is considered the most severe form of viral hepatitis and only occurs in people who also have hepatitis B infection
ICOTYDE is prescribed for adults and children 12 years of age and older who weigh at least 40 kg and have moderate-to-severe plaque psoriasis that may require systemic therapy or phototherapy. Plaque psoriasis is a long-term immune-related skin disease that causes thick, red, scaly patches that can itch, crack, or become painful.
BEQVEZ is prescribed for adults with moderate to severe hemophilia B, a rare inherited bleeding disorder caused by low levels of clotting factor IX. People with hemophilia B can experience serious bleeding episodes, including bleeding into joints, muscles, and internal organs. Many patients require regular factor IX infusions throughout their lives to prevent dangerous bleeding. BEQVEZ is important because it is a one-time gene therapy designed to help the body produce its own factor IX instead of relying on ongoing replacement therapy. This treatment offers a new long-term approach for eligible patients with hemophilia B. The FDA approved BEQVEZ on May 13, 2026.